Tuberculosis and Pulmonary Research Department, TB Protein Chemistry Laboratory, Pasteur Institute of Iran, Pasteur Ave, Tehran, Iran.
Clinical TB and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Immunol Res. 2018 Feb;66(1):59-66. doi: 10.1007/s12026-017-8971-6.
Tuberculosis (TB) is a crucial public health problem with prevalence of multidrug resistant (MDR) rising. An accurate TB biomarker is urgently needed to monitor the response to treatment in patients with MDR tuberculosis. To analyze interaction between selected MDR-TB purified protein and immune cells, dendritic cells from MDR-TB patients and healthy subjects were stimulated by 55KDa protein fractions (Rv0147). The purified proteins identified by proteomic techniques (two-dimensional gel electrophoresis, mass spectrometry) and peptide sequences are known to bind a MHC class I alleles which are extracted from the Immune Epitope Database and Analysis Resource database ( www.iedb.org ). T cells were isolated from PBMC by negative selection and cells were cultured in RPMI-1640 at 37 °C and 5% CO. Cell culture was assayed for cytokine IL-10 and INF-γ by ELISA. We found that INF-γ production was significantly (335 ± 35.5 pg/ml, P ˂ 0.05) upregulated after protein candidate (Rv0147) stimulation by dendritic cells from MDR-TB patients, whereas IL-10 production was greatly reduced compared with production in healthy subjects (212 ± 9.94 pg/ml, P ˂ 0.05). In fact, the purified protein, Rv0147, stimulated dendritic cells from MDR-TB patients, failed to produce IL-10 and directly stimulates INF-γ production by T cells. These results suggest that the purified protein, Rv0147, may stimulate Th1 type protective cytokine response in MDR-TB patients but not in normal subjects. The production of INF-γ but not IL-10 in the presence of purified protein, Rv0147, may be shifted to Th1 responses in MDR-TB patients and supports its potential as protein vaccine candidates against TB.
结核病(TB)是一个严重的公共卫生问题,其多药耐药(MDR)的患病率正在上升。迫切需要一种准确的 TB 生物标志物来监测 MDR 结核患者的治疗反应。为了分析选定的 MDR-TB 纯化蛋白与免疫细胞之间的相互作用,用 55KDa 蛋白片段(Rv0147)刺激 MDR-TB 患者和健康受试者的树突状细胞。通过蛋白质组学技术(二维凝胶电泳、质谱)鉴定的纯化蛋白和肽序列已知与从免疫表位数据库和分析资源数据库(www.iedb.org)提取的 MHC Ⅰ类等位基因结合。通过阴性选择从 PBMC 中分离 T 细胞,并在 37°C 和 5%CO 的 RPMI-1640 中培养细胞。通过 ELISA 测定细胞培养物中细胞因子 IL-10 和 INF-γ的水平。我们发现,MDR-TB 患者的树突状细胞经候选蛋白(Rv0147)刺激后,IFN-γ的产生明显(335±35.5pg/ml,P<0.05)上调,而与健康受试者相比,IL-10 的产生大大降低(212±9.94pg/ml,P<0.05)。事实上,纯化蛋白 Rv0147 刺激 MDR-TB 患者的树突状细胞,不能产生 IL-10,并直接刺激 T 细胞产生 INF-γ。这些结果表明,纯化蛋白 Rv0147 可能刺激 MDR-TB 患者产生 Th1 型保护性细胞因子反应,但在正常受试者中则不然。在纯化蛋白 Rv0147 的存在下产生 INF-γ而不是 IL-10,可能使 MDR-TB 患者向 Th1 反应转移,并支持其作为针对结核病的潜在蛋白疫苗候选物。